SCIENCE

Tomorrow's Medicines
Start Here

Precision Therapeutic Platforms: Delivering Across Biological Barriers

SMDG utilizes platforms invented and developed by Professor Moein Moghimi to design 21st century medicines. Our platforms allow for rapid design and development of new therapies. In addition, the platform allow for screening of new therapeutic complexes and design of more effective small molecules.

Our mission is safe and disease modifying
therapies

NanoLigand Carriers (NLC)

A new Era of Delivery Systems: NanoLigand Carriers (NLC) are a new novel first-in-class nanoparticles. NLCs are unique self-assembled peptididomemtic nanosystems that target the blood-brain barrier as well as other biological barriers. SMDG's innovative and patent-protected NLC technology could be used for targeted delivery of potential therapeutic and diagnostic agents. The NLC technology is based on "safe-by-design" and "simple-by-design" concepts that actively deliver therapeutic and diagnostic molecules to the target cells.

NanoLigand Blocks (NLB)

NanoLigand Blocks (NLB) are a new novel and first-in-class of self-assembled peptidomimetic nanosystems that target biological barriers. SMDG's innovative and patent-protected NLB could be used for targeted delivery of potenial therapeutic and diagnostic agents. NLB is based on "safe-by-design" and "simple-by-design" concepts

Features

SMDG utilizes its 21st century Platforms for Precision Medicine. Our platfoms are designed to allow targeted and receptor mediated therapeutic design and delivery. In addition, the platforms allow rapid screening and identification of new targets and design of new molecules.

Simple and Safe Design

Based on the principles of simple and safe by design

Enabling Active Targeting

Precision Medicine: Intelligent Targeting Technology

allow unprecedented targeting capability

Versatile Cargo Capability

Broad capability beyond the current industry State of the Art with precedented targeting ability for different types of tissues and cargos across biological barriers

Broad Therapeutic Applications

Broad application across neurodegenerative diseases, rare pediatric diseases, immune disorders and oncology.

Learn more about our pipeline

Precision Genetic Medicines

Combining Next Generation of Nucleic Acid - Based Therapeutics and Innovative Technology platform

Designing and Delivering the Next Generation Genetic Medicines

The success of genetic medicines depends not only on designing innovative therapeutic payloads, but on delivering them safely and effectively to their intended target. At SMDG, we are addressing this critical challenge through our proprietary peptide-based NanoLigand™ platforms, engineered to enable precision, receptor-mediated delivery of nucleic acid therapeutics. Our goal is to unlock the next generation of first-in-class disease-modifying therapies for neurological, inflammatory, oncological, and other diseases with significant unmet medical needs.

Advancing research through extended capabilities

Expanded application
broadly to Neurological diseases and immune disorders

Complement and inflammation Platform, known identified receptors

Extensive preclinical studies performed

Advanced Therapies

First-in-Class medicines

Nucleic Acid Delivery

Other significant highlights and advantages of SMDG's R & D programs include simpler and faster, more sustainable and green manufacturing: Much simpler manufacturing than the current industry delivery technology modalities, GMP compliant manufacturing technology and readily scalable.

How we do what we do

Therapeutic targets are studied, analyzed and evaluated based on disease effectiveness. We have performed extensive pre-clinical in-vitro and in-vivo studies and analysis of our therapeutic platforms for delivering candidate therapeutic cargos/payloads.

Delivery of Genetic Medicine (nucleic acid cargos): Therapeutic cargos/nucleic acids are designed and evaluated both in in-vitro and in-vivo. In addition, we collaborate with partners and perform both in-vitro and in-vivo pre-clinical studies on specific disease focused projects.

We design dual and single therapies for several therapeutic candidates.